Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
18th June 2018
We’re thrilled to announce that our clinical lead optometrist, Gillian Bruce, has passed her Masters of Science (MSc) degree in Primary Care Ophthalmology with distinction. As if that wasn’t impre...Read more
24th May 2018
When we first wrote in our blog about Myopia Management over two years ago, it was all quite new. Cameron Optometry was one of the first optometrists in the UK to set up a Myopia Management programme ...Read more